Safe use of oxaliplatin in a patient with metastatic breast cancer and combined renal and hepatic failure

Onkologie

Volumn 29, Issue 6, 2006, Pages 273-275

  Honecker, Friedemann U ^a   Brümmendorf, Tim H ^a   Klein, Oliver ^a   Bokemeyer, Carsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Breast cancer; Hepatic failure; Metastatic; Oxaliplatin; Renal failure

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; GEMCITABINE; OXALIPLATIN; TAMOXIFEN; PLATINUM COMPLEX;

ADULT; ANEMIA; ASCITES; BLOOD TOXICITY; BLOOD TRANSFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; CONFERENCE PAPER; DETERIORATION; DRUG SAFETY; DYSPNEA; ECHOGRAPHY; ELECTROLYTE DISTURBANCE; FEMALE; HEPATORENAL SYNDROME; HOSPITAL ADMISSION; HUMAN; INTRAHEPATIC CHOLESTASIS; JAUNDICE; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER FAILURE; LIVER FUNCTION; LIVER METASTASIS; METASTASIS; NEUROTOXICITY; PERIPHERAL EDEMA; THROMBOCYTOPENIA; ARTICLE; BREAST TUMOR; KIDNEY TUMOR; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; PALLIATIVE THERAPY; TREATMENT OUTCOME;

BREAST NEOPLASMS; FEMALE; HUMANS; KIDNEY FAILURE; KIDNEY NEOPLASMS; LIVER FAILURE; LIVER NEOPLASMS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; TREATMENT OUTCOME;

EID: 33745937899     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093032     Document Type: Conference Paper

References (8)

1. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C: Anti-tumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidilate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997;8:876-885.
2. Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C: Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2002;20:2031-2037.
3. Garufi C, Nistico C, Brienza S, Brienza S, Vaccaro A, D'Ottavio A, Zappala AR, Aschelter AM, Terzoli M: Single agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 2001;12:179-182.
4. Doroshow JH, Synold TW, Gandara D, Mani S, Ramick SC, Mulkerin D, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Granam M, Longmate J, Takimoto CH, Ivy P: Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Sem Oncol 2003;30(suppl 15):14-19.
5. Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow JH, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Greenslade D, Goetz A, Grem JL: Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group study. Sem Oncol 2003;30(suppl 15):20-25.
6. Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow JH, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, Grem JL: Dose escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 2003;21:2664-2672.
7. Gurevich I, Akerley W: Treatment of the jaundiced patient with breast cancer: case report and alternate therapeutic strategies. Cancer 2001;91:660-663.
8. Schüll B, Scheithauer W, Kornek GV: Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. Onkologie 2003;26:578-580.